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Chronic renal allograft injury is often reflected by in-
terstitial fibrosis (IF) and tubular atrophy (TA) with-
out evidence of specific etiology. In most instances,
IF/TA remains an irreversible disorder, representing
a major cause of long-term allograft loss. As mem-
bers of the protease family metzincins and function-
ally related genes are involved in fibrotic and scle-
rotic processes of the extracellular matrix (ECM), we
hypothesized their deregulation in IF/TA. Gene ex-
pression and protein level analyses using allograft
biopsies with and without Banff‘05 classified IF/TA
illustrated their deregulation. Expression profiles of
these genes differentiated IF/TA from Banff‘05 clas-
sified Normal biopsies in three independent microar-
ray studies and demonstrated histological progression
of IF/TA I to III. Significant upregulation of matrix
metalloprotease-7 (MMP-7) and thrombospondin-2
(THBS-2) in IF/TA biopsies and sera was revealed in
two independent patient sets. Furthermore, elevated
THBS-2, osteopontin (SPP1) and b -catenin may play
regulatory roles on MMP. Our findings further suggest
that deregulated ECM remodeling and possibly epithe-
lial to mesenchymal transition (EMT) are implicated in
IF/TA of kidney transplants, and that metzincins and re-
lated genes play an important role in these processes.
Profiling of these genes may be used to complement
IF/TA diagnosis and to disclose IF/TA progression in
kidney transplant recipients.
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Introduction
A leading cause of chronic renal allograft injury (CAI) re-
mains progressive deterioration of kidney function, re-
flected by interstitial fibrosis and tubular atrophy without
evidence of specific etiology (IF/TA), often accompanied
by arterial hypertension and calcineurin inhibitor (CNI) tox-
icity (1). Biopsy-based diagnosis of CAI is often delayed
since clinical indicators manifest themselves typically after
pathohistological alterations have been established (2–5).
To date, there is no specific and effective treatment to
reverse established IF/TA.
Evidence exists, that IF/TA arises at an early stage during
CAI progression (4). Therefore, identification of fibrogenic
factors may complement diagnosis prior to the occurrence
of histological damage and lead to indicative parameters of
IF/TA progression and potential therapeutic targets.
Fibrosis is characterized by accumulation of ECM pro-
teins including deregulation of ECM remodeling (6,7).
ECM remodeling is regulated by the superfamily of met-
zincins (METS), zinc-dependent, metalloproteases (8,9).
These enzymes can be subdivided into a disintegrin and
metalloprotease domain (ADAM), a disintegrin and metal-
loprotease domain with thrombospondin-motif (ADAMTS),
serralysins, papalysins and matrix metalloproteases (MMP)
(8). The latter are the best characterized proteases involved
in ECM remodeling (9,10), and they have been studied in
conditions like inflammation, cancer, arteriosclerosis and
fibrosis (11–15). Most MMP are secreted as inactive pro-
form (zymogen) into the extracellular space, where acti-
vation is accomplished through cleavage of a propeptide
domain (9). Inhibition of MMP occurs by tissue inhibitors of
metalloproteases (TIMP) through 1:1 stoichiometric com-
plexion (9). Metzincins, and especially MMP, function as
matrix remodeling enzymes. They modulate tissue struc-
ture by degradation of collagens, laminins and fibrillin
and by cleaving nonstructural ECM proteins such as la-
tent growth factors, adhesion molecules, chemokines or
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Table 1: Demographic and clinical characteristics of patients included in microarray analyses
N1 IF/TA I1 IF/TA II1 IF/TA III1
Number of biopsies 7 4 10 8
Age of recipient [years]2 45 (+16/−13) 46 (+18/−23) 39 (+18/−15) 40 (+19/−15)
Gender of recipient [%male] 86 75 40 100
Age of donor [years]2,3 44 (+25/−18) 37 (+32/−48) 43 (+18/−26) 51 (+13/−36)
Gender of donor [%male]3 33 75 43 86
Number of HLA mismatches2 1.8 (+2.2/−1.8) 3.3 (+0.8/−1.2) 3.2 (+1.8/−2) 2.5 (+1.5/−2.5)
Time of biopsy [months post tx]2 25 (+125/−25) 76 (+67/−143) 114 (+104/−70) 72 (+111/−63)
Patients with AR episodes prior to MA-bx 1 1 4 4
Number of patients with CsA-based regimen 6 3 7 2
Number of patients with Tac-based regimen 1 1 3 2
Number of patients with mTor-I-based regimen 0 0 0 2
Serum creatinine [lMol/L]2 159 (+51/−55) 155 (+112/−45) 213 (+109/−52) 299 (+196/−107)
GFR (MDRD) [mL/min/1.73 m]2 43 (+20/−18) 45 (+17/−22) 28 (+9/−15) 22 (+10/−17)
1Respective patient groups in GEO: NR; CAN I; CAN II; CAN III.
2Numbers reflect means and range.
3Incomplete initial donor reports in some cases.
CsA = Cyclosporin A; Tac = Tacrolimus; Tx = transplantation; MA-bx = microarray biopsy; mTor-I = mTor inhibitor; GFR = glomerular
filtration rate.
cytokines, and thereby activating and or suppressing cell
signaling pathways involved in proliferation, angiogene-
sis, migration and infiltration (10,16). As one example,
MMP-7 cleaves E-cadherin, beta4-integrin, decorin, proHB-
epidermal growth factor, FasLigand, proTNF-a or plasmino-
gen besides its degradation of fibronectin, collagens I, III-V,
laminin or elastin (17).
During IF/TA development in renal allografts, MMP and
other metzincins may act as fibrogenic factors via their ef-
fect on ECM proteins and signaling pathways (6,9,10,18).
Metzincin-related genes include certain transcription fac-
tors, activators, substrates or inhibitors, as well as spe-
cific cell-surface and cytoplasmic proteins, regulating the
function of metzincins (Table S1). Therefore, we investi-
gated expression of metzincins (METS) and of metzincins
together with their related genes (MARGS) on mRNA and
protein levels utilizing human renal allograft biopsies cat-
egorized into Normals (N) and IF/TA grades I, II, III (Banff
‘05), as well as in IF/TA patient sera.
Materials and Methods
Patients
Biopsies for microarray analyses: Twenty-nine renal allograft biopsies
for cause, primarily due to rising serum creatinine ≥10% above baseline,
were included in microarray analyses. Patients were enrolled at Services de
Néphrologie A and B at Hôpital Tenon, Hôpital Bicetre, Paris and at Hôpital
Pellegrin, Bordeaux, France. Demographic and clinical data are provided in
Table 1.
About two-thirds of a 16-gauge needle-biopsy was processed for
histopathology, the remaining one-third was immediately immersed into
RNAlater (Ambion, Austin, TX) for microarray processing. Histological diag-
nosis was performed by two independent pathologists, and biopsy classifi-
cation, based on Banff ‘05 criteria (5), resulted in 7 Normal (N) and 22 IF/TA
without evidence of specific etiology. N cases were characterized by un-
remarkable histology without signs of CNI-toxicity. Respective N patients
had low CNI trough levels (mean C0 <112 ng/mL), and reduced GFR at
time of biopsy was explained by functional and not structural impairment,
for example, dehydration. Therefore, they served as control group for analy-
ses. The 22 IF/TA cases were graded based on severity of tubulointerstitial
features (ci-/ct-score) into IF/TA I (n = 4), IF/TA II (n = 10) and IF/TA III
(n = 8).
Only four IF/TA biopsies showed very mild tubular cell injury and/or arteriolar
hyalinosis due to CNI treatment, and additional three IF/TA biopsies revealed
suspicious signs of CNI-toxicity. In the remaining 15 IF/TA biopsies, signs
of CNI-toxicity were not observed. IF/TA III donors were distinctively older
than IF/TA I donors, yet their actual biopsies did not reveal major scarring
areas.
Immunosuppression at time of biopsy was based on CNI in 25 cases.
Cyclosporine A (CsA) was used in 18, tacrolimus (Tac) in 7 cases. The re-
maining four patients were either treated by an mTor-inhibitor (mTor-I)-based
regimen (sirolimus; n = 2) or by corticosteroids with or without azathioprine
(Aza; n = 2). CNI and mTor-I treated patients additionally received one or
two of the following: corticosteroids, mycophenolate-mofetil or Aza. Trough
levels (C0) of CsA were generally kept between 110 ng/mL and 150 ng/mL,
Tac C0 levels were targeted at 5–10 ng/mL.
Acute T-cell-mediated, biopsy-proven rejection episodes (AR) prior to biopsy
for the present study were documented for 10 patients (1 N; 9 IF/TA),
dependent on completeness of data. We predominantly found AR I, besides
one in each case of AR II and III. Antibody-mediated AR did not occur.
All patients had given written informed consent, and the local ethical com-
mission had approved the study.
Biopsies for microdissection, subsequent qRT-PCR and immunohis-
tochemistry (IHC): For validation and extension of microarray results, 20
archival, formalin fixed-paraffin embedded (FFPE) renal allograft biopsies
from our institution were used. Biopsies were classified by two indepen-
dent pathologists based on Banff ‘05 (5). Three IF/TA I, 4 IF/TA III and three
N biopsies were used for laser capture microdissection (LCM) and sub-
sequent quantitative real time-PCR (qRT-PCR). IHC was performed using
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6 IF/TA I, 3 IF/TA II, 6 IF/TA III and 5 N biopsies. Biopsies for LCM and IHC
partly originated from the same patients.
Sera for enzyme linked immunosorbent assays (ELISA): For ELISA, we
used serum samples of six patients (1 IF/TA I; 5 IF/TA II) from Hôpitals
Tenon, Paris and Pellegrin, Bordeaux, France, simultaneously collected to
respective microarray-biopsies. Another six serum samples from kidney
transplant patients with stable function (GFR > 90 mL/min) (Ctrl-tx) and
six from healthy volunteers (Ctrl non-tx) were recruited from our institution
serving as age- and sex-matched reference groups.
Preparation of RNA and hybridization of microarrays
RNA was extracted by RNeasy according to the manufacturer’s proto-
col (Qiagen, Hilden, Germany), quantified by ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE) and quality controlled by Bio-
analyzer 2100 (Agilent Technologies, Santa Clara, CA). Aliquots of 50 ng
total RNA were subjected to Affymetrix 2-cycle cDNA amplification, label-
ing, and hybridization to Human Genome U133 Plus 2.0 Arrays, containing
54 120 probe sets representing >47 000 different transcripts (Affymetrix,
Santa Clara, CA) at the Novartis Genomics Factory in Basel, Switzerland
(Affymetrix raw data of biopsies used in our study (Table S2) are available
in gene expression omnibus (GEO), microarray data repository GSE9493
(www.ncbi.nlm.nih.gov/geo).
Laser capture microdissection (LCM)
Twelve 5 lm sections per biopsy were mounted onto polyethylene naphtha-
lene (PEN) -membrane covered slides (P.A.L.M., Microlaser Technologies,
Bernried, Germany), deparaffinized and stained using hematoxylin. LCM
was applied to excise glomeruli, proximal and distal tubules from each
section using the P.A.L.M. MicroBeam system (P.A.L.M. Microlaser Tech-
nologies). Respective kidney units were highlighted, cut and catapulted into
an adhesive tube by a single or several laser shots. All existing glomeruli
(16–191), 240–400 proximal and 240–400 distal tubules were captured and
collected for each patient. Additionally, we scraped off six sections without
glomeruli representing the sample ‘tubulointerstitium’. All samples were
exposed to Protease K (Arcturus, Bucher Biotec AG, Basel, Switzerland)
digestion at 37◦C for 20 h before storage at –80◦C.
PCR of RNA from microdissected tissues
Total RNA was extracted from microdissected kidney elements and tran-
scribed into cDNA using the Paradise Whole Transcript RT Reagent Sys-
tem (Arcturus, Bucher Biotec AG), and Superscript III RT (Invitrogen AG,
Switzerland) was added. All procedures were performed according to
the manufacturer’s protocols under RNase-free conditions; cDNA samples
were stored at –20◦C until gene expression analysis.
QRT-PCR was performed using the 7500 Fast Real Time PCR system
(Applied Biosystems, Rotkreuz, Switzerland) in Standard 7500 run mode
with the following pimers and probes: MMP-7: Hs00159163_m1; MMP-9:
Hs00234579_m1; THBS-2: Hs00170248_m1; 18S rRNA (endogenous con-
trol): Hs99999901_s1 (Applied Biosystems). Samples were run in triplicates
for 40 cycles; a calibrator cDNA sample served as reference value for rela-
tive quantification.
Immunohistochemistry (IHC)
IHC for MMP-7 was performed as previously described using 5 lm FFPE
sections and an antihuman rat monoclonal MMP-7 antibody (19), diluted
1:100. Staining of fibrillin-1 (mouse monoclonal antihuman FBN-1; c = 4
lg/mL; NeoMarkers, Freemont, CA) using 3 lm FFPE sections was per-
formed as previously published (20). However, for development, a polymer-
system consisting of antimouse antibodies and horseradish peroxidase en-
zymes bound to a dextran backbone (Envision; Dako, Glostrup, Denmark)
was applied for 30 min, followed by 0.1% 3,3’-diaminobenzidine and 0.03%
H2O2 development, counterstaining and mounting.
We scanned the slides using Scan Scope CS System, and Image Scan
Scope software v.9.0 was applied for semiquantification (Aperio, Vista, CA).
An algorithm counting stain specific positive pixels was used and, in relation
to total number of pixels and scanned area, defined as positivity of staining.
ELISA
Quantikine ELISA kits for pro-/active MMP-7, pro-/active MMP-2, THBS-2
and SPP1 from R&D (R&D Systems Europe Ltd, Abingdon, UK) were used
according to the manufacturer’s protocol. Samples were run in triplicates.
Statistics
Microarrays: Microarray cell intensity (CEL) files were analyzed with
Partek Genomics Suite v.6.3 (www.partek.com). Files were subjected
to Robust MultiChip Analyses (RMA), quantile normalization with back-
ground correction and log2 transformation. Model-dependent undesired
technical processing-related variance was treated by least squared mean
adjustment.
For classifier identification, ANOVA and Shrinking Centroids methods were
used for variable selection, and a variety of classification methods, such
as K-nearest neighbor (KNN) and discriminant analysis (DA) were tested.
To limit type 1-error, leave-one-out method was performed for internal
cross-validation (21). An internal split into training- and test-set would
have resulted in groups with too few samples. The model with the high-
est specificity/sensitivity was applied to external data sets that were
downloaded from public data repositories. The ‘Edmonton’ data set is
found on http://transplants.med.ualberta.ca (22), and the ‘Stanford’ data
set was downloaded from the GEO microarray data repository (GEO343;
www.ncbi.nlm.nih.gov/geo) (23). Mapping of Affymetrix probe sets to Stan-
ford array clones of a ‘lymphochip’ was done by annotation, and missing
values were added as median per clone. Only probe sets having expression
levels ≥100 in ≥4 samples in our data set were used. Similarly, only clones
having data in at least 70% of samples were considered.
Gene set enrichment analysis (GSEA) (www.broad.mit.edu) was applied to
detect enriched gene sets in a data set, as described earlier (24).
We estimated the relationship between METS and MARGS and histological
Banff ci- and ct-scores based on a previous publication (22). Gene set scores
for each IF/TA biopsy were calculated as the mean of fold changes of each
probe set relative to the mean expression level of the same probe set in N.
METS and MARGS scores were then grouped according to respective ci-
or ct-score as the group mean, and 2-tailed p-values were calculated.
PCR and ELISA: QRT-PCR data were analyzed using Sequence Detection
Software v.1.4 (Applied Biosystems) and Excel 2005 (Microsoft Office 2000,
Microsoft, Redmond, WA). Delta () Ct values were calculated for all sam-
ples. Based on Ct values of the internal calibrator sample, gene expression
fold changes (fc) were computed for IF/TA I, IF/TA III and N (Ct method).
Analysis of ELISA was performed in Microsoft Excel 2005.
Significance of differential mRNA expression and protein concentrations
in IF/TA was calculated in Graph Pad Prism v.5.01 (Graph Pad Software
Inc., LaJolla, CA) applying Mann–Whitney U-test with a p-value < 0.05
as significant. Results are given as mean values plus standard error of
mean.
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Figure 1: IF/TA grade-dependent
expression changes of METS and
MARGS. Probe sets with up- (A, B)
or downregulation (C, D) in IF/TA com-
pared to N are plotted: on the x-axis
mean expression levels of probe sets
in N and on the y-axis correspond-
ing expression levels in IF/TA. Each
dot represents one probe set. Equa-
tions were obtained by linear regres-
sion of data points. Slope values >1
reflect overrepresentation and <1 un-
derrepresentation of genes compared
to expression in N; exclusion of 4
MARGS probe sets due to probe sat-
uration effects. (A) Upregulated METS
(64 probe sets) and (B) upregulated
MARGS (213 probe sets) in IF/TA III
with respective values for IF/TA II and
I. (C) Downregulated METS (93 probe
sets) and (D) downregulated MARGS
(209 probe sets) in IF/TA III and re-
spective data for IF/TA I and II.
Results
Microarray analysis
We examined expression changes of METS (n = 76) and
MARGS (n = 157) (Table S1), in increasing grades of IF/TA.
Among METS, 41% of probe sets, and among MARGS,
50% of probe sets showed increased mean signal intensi-
ties with a steady rise from IF/TA I to II and III, as indicated
by the increasing slopes of respective regression curves
(Figure 1A, B). IF/TA grade-dependent decrease of signal
intensities for probe sets having lower than N expression
levels in IF/TA III is illustrated in Figure 1C (METS) and 1D
(MARGS).
Figure 2: Principal component
analysis (PCA) of ANOVA fil-
tered probe sets illustrates his-
tological IF/TA progression. (A)
PCA based on 5 METS probe
sets with p ≤ 0.0001, repre-
senting 4 genes. (B) PCA based
on 12 MARGS probe sets with
p ≤ 0.0001, representing 8 genes.
PCA revealed a trend of IF/TA
grade-dependent transition from
N to IF/TA III. Probe set lists were
generated by ANOVA across all pa-
tient groups. The ellipsoids con-
tain data points of the individual
groups with a standard deviation
of 3.0.
ANOVA was performed with both gene sets on all four
sample groups to identify probe sets with significant ex-
pression differences explaining the variance between in-
dividual sample groups. Five METS probe sets and 12
MARGS probe sets (p ≤ 0.0001) explained about 66% of
the variance between N, IF/TA I, -II, and IF/TA III in the
first component of a principal component analysis (PCA)
(Figure 2A, B). PCA revealed an IF/TA grade-dependent
transition from N to IF/TA II and -III, while IF/TA I samples
appeared to be close to N.
To test the potential of METS as molecular markers of
IF/TA, we calculated sensitivity, specificity and accuracy of
more than 1500 models, using gene expression data of our,
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Table 2: Classification performance using a linear discriminant
model based on 26 probe sets coding for 20 MARGS
Correct
classification Sensitivity Specificity
rate [%] [%] [%]
Present study (n = 29) 100 100 100
Edmonton (22) (n = 17) 88 75 100
Stanford (23) (n = 31) 77 67 88
as well as two external, independent data sets: included
were 7 N and 22 IF/TA samples of our, 8 N and 9 IF/TA
samples of the ‘Edmonton’ and 15 N and 16 IF/TA sam-
ples of the ‘Stanford’ data set. One model categorized our
data set in agreement with histopathological readings and
was based on METS. As the accuracy of the external data
was insufficient, we repeated analyses applying MARGS.
A linear DA with 26 probe sets, including ADAMTSL3,
ADAMTS5, ADAM28, THBS-1 and -2 (Table S3), correctly
classified all samples in our data set and showed 88% cor-
rect assignment of ‘Edmonton’ (22) (sensitivity 75%, speci-
ficity 100%), and 76% correct assignment of ‘Stanford’
(23) samples (sensitivity 67%, specificity 87%) (Table 2).
To examine possible pathways and molecular processes
underlying IF/TA in comparison to normal allografts, we
subjected the expression data of IF/TA and N samples to
GSEA with 1252 gene sets from various sources. Result-
ing gene sets contained numerous members of METS or
MARGS (Figure 3A–F).
One gene set with enrichment in IF/TA is ‘Human Extracel-
lular Matrix and Adhesion Molecules’ (ECM; SABioscience
Corporation, Frederick, MD) containing MMP, MMP sub-
strates, TIMP, SPP-1, THBS -1,-2,-3 as well as other struc-
tural and signaling ECM proteins (Figure 3A).
Figure 3: Gene sets reflecting
potential pathogenic processes
underlying IF/TA are enriched
in IF/TA biopsies and include
MARGS. GSEA identified path-
ways and gene sets enriched in
IF/TA samples (IF/TA I, II, III com-
bined; n = 22). Mean signal in-
tensities for N (n = 7) and IF/TA
are plotted. (A) ‘ECM’: ECM and
adhesion molecules; 195 probe
sets (B) ‘EMT’: 360 probe sets
(C) ‘Wnt-pathway’: 94 probe sets;
(D) ‘TGFbeta-signaling pathway’:
281 probe sets; (E) ‘Aging kid-
ney_down’, 366 probe sets; genes
downregulated in aging kidneys.
Similarly, members of the gene set ‘epithelial to mes-
enchymal transition’ (EMT; based on (25)) were significantly
augmented in IF/TA compared to N (Figure 3B). ‘EMT’ in-
cludes many MMP substrates concerning cell structure,
adhesion and signaling. GSEA further associated IF/TA to
the winglesstype signaling pathway (Wnt; SABioscience
Corporation), including b-catenin (Figure 3D). A potential
relation between Wnt-signaling, b-catenin, MMP-7 expres-
sion and IF/TA is discussed below. Another gene set illus-
trating IF/TA involvement is the signaling pathway trans-
forming growth factor-beta (TGF-b) (26) (Figure 3E). On the
contrary, members of the gene set ‘Aging kidney down’
(27), which includes genes with underrepresentation in
senescent human renal biopsies, showed enrichment in
our N biopsies (Figure 3E) implying that aging related—
processes may be involved in IF/TA development.
Next, we focused on the relationship between METS and
MARGS and individual Banff scores (ci, ct, cv). Eighteen
METS and 89 MARGS probe sets with absolute fc ≥1.5
from N to IF/TA III were included in the analyses. Figure 4
illustrates that increasing expression fc for METS and
MARGS relate to rising ci- and ct-scores with significant
correlation between ci3 and ci2/ci1 and between ct3 and
ct1. No significant correlation was observed for cv scores
(data not shown). Generally, METS performed better than
MARGS.
Based on the results of microarray analyses and previ-
ous studies (28), we selected 17 genes for more de-
tailed investigations. Selection criteria comprised extent
of over-/underrepresentation in IF/TA, known involvement
in fibrogenesis and ECM remodeling and implication in fi-
brotic diseases of other organs (10,12,14). Figure 5 illus-
trates that for most of these genes expression fc (log2
transformed) to N rose concurrently to IF/TA progression.
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Figure 4: Relationship of METS
and MARGS to individual Banff
scores. Mean expression levels
of individual METS- and MARGS-
scores (log2 ± SEM) are plotted
for (A) increasing grades of lF (ci1–
3) and (B) increasing grades of TA
(ct1–3). The p-values were calcu-
lated by 2-sided t-test. ∗p ≤ 0.05;
∗∗p ≤ 0.01.
Highest expression in IF/TA III was observed for MMP-7
and THBS-2 (log2 fc = 1.4; respectively 1.7).
qRT-PCR of RNA from microdissected glomeruli,
tubuli and tubulointerstitium
Glomerular, proximal- and distal tubular as well as tubuloin-
terstitial gene expression in N, IF/TA I and IF/TA III were
calculated as mean fold change to expression in the inter-
nal calibrator sample (Figure 6).
Significant overexpression of MMP-7 (Figure 6A) and
THBS-2 (Figure 6B) was observed in all isolated kidney
units of IF/TA I and -III biopsies compared to N, except
THBS-2 in distal tubules. Both genes showed highest
mRNA levels in proximal tubules of IF/TA I biopsies (MMP-
7, fc = 26; THBS-2, fc = 33). Glomerular expression of
MMP-7 and THBS-2 was low in N, but increased in IF/TA I
(p < 0.05) –III (p < 0.001). Glomerular and tubular expres-
sion of MMP-9 were specifically elevated in IF/TA I (data
not shown).
Immunohistochemistry
IHC revealed accumulation of MMP-7 and FBN-I in IF/TA
I and -III biopsies compared to N (Figure 7). In confor-
mity with qRT-PCR results, protein MMP-7 levels in IF/TA
Figure 5: Gene expression changes
of 17 MARGS. Relative expression
log2 mean ratio to N of selected
32 probe sets monitored by mi-
croarray analyses are plotted for
three patient groups with increas-
ing IF/TA grade. Mean values were
calculated for ADAM12, ADAM17,
ADAM28, COL1A1, FBN1, LAMA2,
PLG, TIMP2, TIMP3, represented by
several probe sets. Log2 values >0
illustrate increased, <0 decreased ex-
pression compared to N.
biopsies were more intense in tubules than glomeruli.
There were particularly increased MMP-7 levels in distal
tubules of IF/TA III (Figure 7C). FBN-I levels were inten-
sified in the interstitium (Figure 7G) and increased from
N to IF/TA III confirming microarray findings. Calculated
positivity of stainings further supported our observations
(Figure 7D, H).
IHC for MMP-2, -9 and TIMP-2 did not lead to identification
of a distinct pattern (data not shown).
ELISA of serum samples
Investigations of circulating MMP-2, -7, THBS-2 and SPP-1
levels revealed increased concentrations in IF/TA patients
compared to transplanted patients with stable function
(Ctrl-tx) or healthy volunteers (Ctrl non-tx) (Figure 8). Differ-
ences between IF/TA and control groups were statistically
significant in all cases, except THBS-2 versus Ctrl-tx. MMP-
7, THBS-2 and SPP-1 progressively rose from Ctrl non-tx
to Ctrl tx to IF/TA. Interestingly, Ctrl non-tx already signifi-
cantly deviated from Ctrl-tx with regard to MMP-2, -7 and
SPP-1 (Figure 8A, C, D). Protein levels were more homoge-
nously distributed within the control groups compared to
IF/TA.
Additional ELISA for MMP-3/-9 and TGF-b 1 were inconclu-
sive (data not shown).
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Figure 6: Glomerular and tubular MMP-7 and THBS-2 mRNA levels are augmented in IF/TA I and IF/TA III. Expression of MMP-7
and THBS-2 in microdissected kidney elements of three patient groups (N; IF/TA I; IF/TA III) is illustrated as fc to expression in the internal
calibrator sample (A) MMP-7 expression changes in glomeruli, proximal-, distal tubules and tubulointerstitium, (B) respective values for
THBS-2. The p-values were calculated by Mann–Whitney U-test; ∗p ≤ 0.05; ∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001.
Discussion
This study was performed to investigate the role of met-
zincins and related genes (METS and MARGS) in IF/TA
without evidence of specific etiology. Gene and protein
expression analyses were performed in independent sets
of clinically indicated renal allograft biopsies (biopsies for
cause) and in respective patient sera.
To identify differences in expression based on IF/TA de-
velopment, we chose biopsies histologically classified as
Figure 7: Immunohistology shows increased glomerular and tubular MMP-7 and interstitial FBN-I. MMP-7 and FBN-I IHC of
sections from Normal (N), IF/TA I, and IF/TA III. Representative pictures for MMP-7 are shown in (A) Normal (N); (B) IF/TA I; (C) IF/TA III
biopsies and (D) semiquantification of MMP-7 staining intensity. (E–H) with respective results for FBN-I IHC.
‘Normal’ (Banff ‘05) as control group, despite transient
functional impairment. Likelihood for normal histology was
increased by the low threshold of biopsy indication. Nev-
ertheless, protocol biopsies of recipients with normal allo-
graft function would present an even better control group.
With the help of genechip technology, we identified dif-
ferences between IF/TA and N based on the expression
profiles of METS and MARGS and distinguished deregu-
lated key genes with respect to IF/TA classification and
progression.
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Figure 8: Identification of augmented MMP-7, THBS-2, SPP1
and MMP-2 serum levels. ELISA demonstrated elevated concen-
trations of MMP-7, MMP-2, THBS-2 and SPP1 in the circulation of
patients with IF/TA I, II. Each dot represents one sample, and the
lines represent mean serum levels.
Our analyses focused on metzincins due to their biolog-
ical function as ECM-degrading enzymes and their role
in activation and suppression of cell signaling pathways
with regard to tissue remodeling (9,18). MMP are known
to be deregulated in fibrogenic processes, for example,
pulmonary, liver and heart fibrosis as well as during pro-
gressive kidney scarring (11–14). We previously showed a
significant increase of several METS, including MMP, TIMP
and ADAM in the established Fisher (F344) to Lewis (LEW)
rat model of chronic renal allograft rejection (28).
Little is known about the role of MMPs, metzincins and
related genes in human IF/TA. A deregulation of METS and
MARGS on mRNA and protein level may indeed contribute
to the pathogenesis of IF/TA with respect to their role in
fibrosis.
Excessive ECM deposition can be accelerated by EMT, and
transition of tubular epithelial to mesenchymal cells has
been linked to kidney fibrosis (29,30). IF/TA biopsies of our
study showed enrichment of EMT-related genes including
metzincins and related genes. Alterations in the cellular
composition of tissue, for example, the kidney, including
an increase of mesenchymal cells may lead to modulated
metzincin expression (17,31,32).
Wnt-signaling can induce EMT and may be involved in re-
nal fibrosis (15,33–36). One target gene of Wnt-signaling is
MMP-7 with b-catenin promoting its expression (37). IF/TA
biopsies of our study revealed Wnt-signaling involvement,
and we observed increasing b-catenin levels during IF/TA
progression (data not shown). One consequence of acti-
vated Wnt-/ b-catenin signaling may be overexpression of
MMP-7, as we observed in IF/TA biopsies. Overexpression
of b-catenin in chondrocytes led to increased expression of
MMP-7 (38). Our results of tubulointerstitial MMP-7 over-
expression in IF/TA agree with findings of others (39,40).
In addition, we identified glomerular MMP-7 levels to be
increased early during IF/TA, and a preferential distal tubu-
lar expression of MMP-7 during progression of IF/TA that
was confirmed on the protein level. Furthermore, we dis-
covered elevated MMP-7 levels in IF/TA patient sera.
Elevated mRNA and protein levels in IF/TA patient biopsies
and sera were also found for THBS-2. Analyses showed a
positive proportionality between increasing THBS-2 mRNA
expression levels and IF/TA progression from N to IF/TA I,
-II, -III, together with an inverse proportionality to GFR of
IF/TA patients (data not shown).
Importantly, our second patient set revealed upregulated
mRNA levels of MMP-7 and THBS-2 and increased MMP-7
production already in IF/TA I.
To the best of our knowledge, involvement of THBS-2 in
IF/TA has not been reported so far. Others identified THBS-
1 as profibrotic factor in IF/TA (40). We saw a twofold
augmentation of THBS-1 in the IF/TA patients of our co-
hort. Since the respective value for THBS-2 was threefold,
we further investigated THBS-2. Increase of THBS-2 may
lead to decrease of MMP activity, possibly through direct
binding (41). Investigating MMP-2, we found insignificant
changes in biopsies, however, IF/TA patient sera displayed
elevated levels.
Another molecule with overexpression on mRNA and on
protein level in IF/TA was SPP-1 that modulates fibroblast
secretion of MMP (42–44). Others identified SPP-1 over-
expression and an interaction with MMP-7 in patients with
pulmonary fibrosis (45).
Of interest is also the increase of FBN-I, detected on
mRNA and protein level in IF/TA. FBN-I represents a po-
tential substrate of MMP-7 (46). Predominantly, MMP-7
was found in tubules whereas FBN-I was present in the
interstitium.
The findings of our study support a pathogenic role of
MMP and their regulators in IF/TA, possibly even indicat-
ing novel therapeutic targets for IF/TA treatment. Interven-
tional studies need to validate these findings and may con-
sist of selective MMP (e.g. MMP-7) inhibition. In a mouse
model of cardiac rejection, broad systemic MMP- and
ADAM-inhibition by doxycycline significantly enhanced al-
lograft survival (47). Doxycycline can indeed inhibit MMP-7
activity (48). Furthermore, early MMP-inhibition by BAY12–
9566 resulted in reduced proteinuria associated with an
amelioration of IF/TA in rats (49). Sirolimus ameliorated en-
hanced MMP-2/–9 expression in a rat model of autosomal
polycystic disease (50).
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The potential of METS and MARGS to complement iden-
tification of IF/TA and to indicate progression from N
to IF/TA III was supported by the correlation between
METS/MARGS and the IF/TA relevant Banff scores ci and
ct; there was no correlation with cv scores.
These findings together with linear DA and PCA results for
METS and MARGS may be useful to define IF/TA based on
genechip technology.
We acknowledge, that our study was primarily limited by
a relative small sample size. Microarray data validation in
two external data sets and performance of multiple expres-
sion analyses using two independent patient populations
increased the explanatory power of our analyses and ad-
dressed the limiting number of patients. Another limiting
factor was the discrepancy between IF/TA I and III patients
with respect to donor age. The effect of donor age on our
study is difficult to assess due to the small data set, the
lack of an independent validation set and the absence of
implant biopsies.
Based on our present findings, we conclude, that deregu-
lation of METS and MARGS in IF/TA, especially MMP-7, is
able to reflect disease progression and to differentiate this
disorder from normal tissue. Patient monitoring applying a
transcript-set including these genes might support identi-
fication of IF/TA in patients after renal transplantation.
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